GS1-144錠剤単回経口投与後のPKに対する喫煙の影響を評価する。
中国人健康閉経後女性被験者におけるGS1-144錠剤単回経口投与後の薬物動態に対する喫煙(CYP1A2誘導剤)の影響を評価する薬物相互作用試験
A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This drug-drug interaction study adopts an open-label, parallel design to evaluate the effect of smoking on the PK following a single oral dose of GS1-144 tablets in Chinese healthy postmenopausal female trial participants.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Jinan
-
Shandong、Jinan、中国、100021
- The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
1)40 to 65 years of age (inclusive) at the time of signing the informed consent form (ICF).
2)Trial participants are healthy females who meet any of the following criteria during screening:
-
Consecutive spontaneous amenorrhea ≥ 12 months.
-
Consecutive spontaneous amenorrhea ≥ 6 months but < 12 months, with serum follicle-stimulating hormone (FSH) levels > 40 IU/L.
-
≥ 6 weeks after bilateral oophorectomy.
-
History of hysterectomy with preservation of one or both ovaries and FSH levels > 40 IU/L.
3)Body weight ≥ 45 kg, and body mass index (BMI) within the range of 18-28 kg/m2 (inclusive).
4)Able to communicate well with the investigator, understand and comply with all study requirements, voluntarily agree to participate in the trial, and understand and voluntarily sign the ICF.
5)Smoker:smoking ≥ 10 cigarettes per day within 6 months prior to screening, and urinary cotinine level ≥ 1,000 ng/mL at screening. Smokers will be required to continue smoking in designated areas according to their habits during the study.
6)Non-smoker: no smoking within 6 months prior to screening, and urinary cotinine level < 200 ng/mL at screening.
Exclusion Criteria:
- Known history of hypersensitivity to the investigational drug, any of its excipients, or related formulations; or a history of allergic disorders (including but not limited to asthma, urticaria); or being allergy-prone (e.g., known allergy to two or more substances).
- History or current diagnosis of diseases of the circulatory, digestive, urinary, respiratory, endocrine and metabolic, hematological and lymphatic, immune, psychiatric and neurological, or dermatological systems, and deemed unsuitable for participation by the investigator.
- History of severe infection, serious trauma, or major surgery within 6 months prior to screening, or planning to undergo surgery during the trial.
- Blood donation or blood loss ≥ 400 mL, or receipt of blood transfusion within 3 months prior to screening, or planning to donate blood within 1 month after the end of the trial.
- Use of any prescription medications [including but not limited to drugs known to alter hepatic enzyme activity (e.g., glucocorticoids, sex hormones, anticonvulsants, cyclosporine)] within 4 weeks prior to screening, or use of any over-the-counter (OTC) medications (including but not limited to herbal medicines, herbal compound prescriptions, health supplements) or vitamin supplements within 2 weeks prior to screening.
- Trial participants with abnormal findings in physical examination, chest X-ray, abdominal and urinary ultrasound, genital ultrasound, thyroid and parathyroid ultrasound, or laboratory tests at screening, which are deemed unsuitable for participation by the investigator.
- During screening or on D-1, any of the following liver function test results as follows: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 1.5 × upper limit of normal (ULN), or total bilirubin (TBIL) ≥ 1.2 × ULN.
- Abnormal vital signs and deemed unsuitable for participation by the investigator, or systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg during screening.
- Abnormal 12-lead ECG findings and deemed unsuitable for participation by the investigator, or QTcF > 470 ms (Fridericia's formula: QTcF = QT/RR0.33, RR = 60/heart rate) during screening.
- Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TP-Ab) during screening.
- Participation in another clinical trial within 3 months prior to screening (except for trial participants who did not receive any investigational intervention), or current participation in any other clinical trial.
- Current or past history of drug abuse within 1 year, or positive urine multi-drug test panel.
- Positive alcohol breath test or history of excessive alcohol consumption (defined as >14 units of alcohol per week) within 3 months prior to screening (One standard alcohol unit is equivalent to 17.5 mL or 14 g of pure ethanol. Alcohol content is labeled by volume (ABV) for all beverage types. This corresponds approximately to 35 mL of 50% spirits or 350 mL of 5% beer), or unwillingness to abstain from alcohol or any alcohol-containing products during the trial.
- Consumption of food or beverages that may affect drug metabolism (e.g., containing grapefruit, starfruit, or their products) within 48 hours prior to admission.
- Excessive consumption of tea, coffee, or caffeinated beverages (>8 cups per day, 1 cup=250 mL) within 3 months prior to screening; or consumption of any food or beverage containing or metabolized to caffeine or xanthine (e.g., coffee, tea, chocolate, cola) within 24 hours prior to admission.
- Pregnant or lactating women, or those who have a clinically significant positive pregnancy test result.
- Poor venous access, a history of difficult venipuncture, intolerance to venipuncture/intravenous indwelling needle, or needle/blood phobia.
- Other conditions deemed unsuitable by the investigator.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:GS1-144錠
|
All trial participants will receive the investigational drug (GS1-144 tablets) at a dose of 30 mg. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
GS1-144の主要なPKパラメータ:Cmax。
時間枠:最大72時間
|
最大72時間
|
|
GS1-144の主要なPKパラメーター:AUC0-t。
時間枠:最大72時間
|
最大72時間
|
|
GS1-144の主要なPKパラメータ:AUC0-∞。
時間枠:最大72時間
|
最大72時間
|
|
GS1-144の二次的PKパラメータ:Tmax。
時間枠:最大72時間
|
最大72時間
|
|
GS1-144の二次的PKパラメータ:消失速度定数(λz)。
時間枠:最大72時間
|
最大72時間
|
|
GS1-144の二次的PKパラメータ:t1/2
時間枠:最大72時間
|
最大72時間
|
|
GS1-144の二次的PKパラメータ:CL/F。
時間枠:最大72時間
|
最大72時間
|
|
GS1-144の二次的PKパラメータ:Vd/F。
時間枠:最大72時間
|
最大72時間
|
|
GS1-144の二次的PKパラメータ:AUC_%Extrap。
時間枠:最大72時間
|
最大72時間
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
主要代謝物M1のPKパラメータ:Cmax。
時間枠:最大72時間
|
最大72時間
|
|
主要代謝物M1のPKパラメータ:AUC0-t。
時間枠:最大72時間
|
最大72時間
|
|
主要代謝物M1のPKパラメータ:AUC0-∞。
時間枠:最大72時間
|
最大72時間
|
|
主代謝物M1のPKパラメータ:Tmax。
時間枠:最大72時間
|
最大72時間
|
|
主要代謝物M1のPKパラメーター:λz。
時間枠:最大72時間
|
最大72時間
|
|
主要代謝物M1のPKパラメータ: t1/2。
時間枠:最大72時間
|
最大72時間
|
|
主要代謝物M1のPKパラメータ:AUC_%Extrap。
時間枠:最大72時間
|
最大72時間
|
|
有害事象(AEs)。
時間枠:最大72時間
|
最大72時間
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- GenSci074-107
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。